THE PARLIAMENTARY PANEL’S RECOMMENDATION
The Parliamentary Standing Committee on Union Ministry of Chemicals and Fertilisers has recently asked the Department of Pharmaceuticals (DoP) to take corrective steps to remove any administrative and procedural delays related to the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme. The Panel’s recommendation comes in the wake of its observation that despite restructuring of the scheme, issuance of revised guidelines, strengthening of monitoring and review mechanisms, an amount of Rs. 181.72 crore only out of Rs. 245 crore allocated at Revised Estimates (RE) stage i.e. 74 per cent of RE allocation could be utilised in the Financial Year 2025-26. The Panel headed by Member of Parliament Kirti Azad Jha further recommend to the DoP to initiate concrete steps to ensure optimal utilisation of allocated funds in the ongoing and coming financial years. It is a fact that ever since the scheme was launched by the Central government in August, 2023 to transform the Indian pharma and med-tech sectors from cost-based to innovation-based growth by strengthening the research infrastructure in the country, the scheme has been moving at a snail’s pace. Of course, the DoP should have taken proactive measures to implement a prominent scheme like PRIP scheme which was notified by the DoP with an approved outlay of Rs. 5,000 crore, aiming at promoting industry-academia linkage for R&D in priority areas and to inculcate the culture of quality research and nurture the nation's pool of scientists. The scheme offers the pharmaceutical industry an opportunity to build IP-driven products and not just remain a generics powerhouse. No doubt, the scheme marks a decisive policy shift, one that redefines Indian pharma’s trajectory from replication to innovation. By actively supporting drug discovery, biosimilars, and complex generics, it sends a clear message to the world that India is ready to lead not just in affordability, but in invention also.
No doubt, by launching a scheme like PRIP scheme, the Central government has initiated a new policy intervention, which will definitely prove to be a watershed moment in India’s journey towards global leadership in healthcare innovation. Of course, PRIP scheme will help transform the Indian pharma and med-tech sectors from cost-based to innovation-based growth by strengthening the research infrastructure in the country. The scheme will promote industry-academia linkage for R&D in priority areas and will inculcate the culture of quality research and nurture our pool of scientists. This will lead to sustained global competitive advantage and contribute to quality employment generation in the country. By providing a conducive environment for innovative research, India can effectively leverage its scientific talent to generate ground-breaking solutions to address pressing global medical challenges. Certainly, focusing on certain priority areas will help Indian pharma industry leapfrog and radically strengthen its position in the world market and building world class research atmosphere at NIPERs by establishing CoEs will make a talent pool of qualified scientists. At present, a major component of Indian exports are low value generic drugs while a large-proportion of the demand for patented drugs is met through imports. This is because the Indian pharmaceutical sector lacks in high value production along with world class pharma R&D. To encourage the global and domestic players to enhance investment and production in these product categories, a well-designed and suitably targeted policy intervention was required to promote specific high value goods such as bio-pharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, cell based or gene therapy drugs, etc. By weaving together regulatory reforms, investment incentives, targeted funding and a vibrant ecosystem, the PRIP scheme can unlock the untapped potential of its scientific community, nurture breakthrough solutions that transcend borders and elevate its stature to a global innovation hub for pharma and med-tech sectors. So, the DoP should not be found wanting in taking corrective steps to remove any administrative and procedural delays in implementing the PRIP scheme in letter and spirit.